Sustained benefit of zanubrutinib in relapsed/refractory (R/R) marginal zone lymphoma: MAGNOLIA + LTE1

ASH 2026 • MZL • Zanubrutinib • Poster

Stephen S. Opat, MBBS

DISCLAIMER

The contents of the presentation are designed for educational and scientific exchange purposes and are not promotional. They may contain information on investigational products or investigational uses of approved products. No conclusions regarding safety and/or efficacy for such investigational products or uses may be made.

SUMMARY

MAGNOLIA was an open-label, single-arm, multicenter phase 2 study of zanubrutinib in relapsed/refractory marginal zone lymphoma. This ad hoc analysis reported up to 7 years of follow-up from MAGNOLIA, and its long-term extension (LTE1). Of 68 enrolled patients, 66 were evaluable for efficacy; 36 patients (52.9%) rolled over to LTE1. As of April 1, 2026, at a median study follow-up of 35.3 months (range, 1.6-84.3), investigator-assessed overall response rate was 77.3% (95% CI, 65.3-86.7) and complete response was 37.9% (95% CI, 26.2-50.7). Median duration of response was 38.8 months (95% CI, 22.1-not estimable), median progression-free survival (PFS) was 34.3 months (95% CI, 16.5-49.6), and median overall survival (OS) was not reached. At 72 months, PFS and OS rates were 36.1% (95% CI, 24.3-48.0) and 72.0% (95% CI, 58.0-82.1), respectively. Median treatment exposure was 27.8 months (range, 0.9-82.0), with 52.9% of patients treated for >2 years and 35.3% for >4 years. Grade ≥3 treatment-emergent adverse events (TEAEs) occurred in 60.3% of patients, serious TEAEs in 52.9%, TEAEs leading to discontinuations in 8.8%, and fatal TEAEs in 8.8% (2.9% were due to COVID-19 pneumonia).

ClinicalTrials.gov IDs: NCT03846427 (MAGNOLIA), NCT04170283 (LTE1)

Population Intervention / Exposure Comparator Outcomes
Patients with relapsed/refractory marginal zone lymphoma enrolled in MAGNOLIA and followed in the long-term extension (LTE1) Zanubrutinib N/A Overall response rate, complete response rate, duration of response, progression-free survival, overall survival, and safety

FAQs

This ad hoc analysis reported up to 7 years of integrated efficacy and safety follow-up from MAGNOLIA, an open-label, single-arm, multicenter phase 2 study of zanubrutinib in patients with relapsed/refractory (R/R) marginal zone lymphoma (MZL), and its long-term extension (LTE1).

MAGNOLIA was an open-label, single-arm, multicenter phase 2 study of zanubrutinib in patients with R/R MZL. Patients enrolling in LTE1 continued zanubrutinib at the same dose received in MAGNOLIA. This ad hoc analysis integrated efficacy and safety data across both studies. Safety was assessed every 3 months, while efficacy was evaluated every 6 months with regular restaging scans at the investigators’ discretion. All disease progression events were independently confirmed. Efficacy endpoints included investigator-assessed overall response rate (ORR), complete response (CR) rate, duration of response (DOR), progression-free survival (PFS), and overall survival (OS); safety was also assessed.

Of 68 patients enrolled in MAGNOLIA, 66 were evaluable for efficacy. Thirty-six patients (52.9%) rolled over to LTE1, of whom 32 (47.1%) continued treatment with zanubrutinib and 4 (5.9%) were in survival follow-up. As of April 1, 2026, median study follow-up was 35.3 months (range, 1.6-84.3), with the longest individual follow-up reaching 7 years. Median treatment exposure across MAGNOLIA and LTE1 was 27.8 months (range, 0.9-82.0); 36 patients (52.9%) were treated for more than 2 years and 24 (35.3%) for more than 4 years.

The investigator-assessed ORR was 77.3% (95% CI, 65.3-86.7). With approximately 4 years of extended follow-up, the CR rate increased to 37.9% (95% CI, 26.2-50.7) from 28.8% at study closure of MAGNOLIA, with five patients previously assessed as partial response and one as stable disease converting to CR since the study closure of MAGNOLIA. Median time to response was 2.99 months.

 

Median DOR was 38.8 months (95% CI, 22.1-not estimable); DOR rates were 58.4% (95% CI, 43.5-70.6) at 36 months and 47.5% (95% CI, 33.0-60.6) at 60 months. Median PFS was 34.3 months (95% CI, 16.5-49.6); PFS rates were 48.1% (95% CI, 35.4-59.8) at 36 months, 37.8% (95% CI, 25.8-49.7) at 60 months, and 36.1% (95% CI, 24.3-48.0) at 72 months. Median OS was not reached; OS rates were 74.4% (95% CI, 60.8-83.9) at 60 months and 72.0% (95% CI, 58.0-82.1) at 72 months.

Serious treatment-emergent adverse events (TEAEs) occurred in 52.9% (n=36) of patients, grade ≥3 TEAEs in 60.3% (n=41), TEAEs leading to treatment discontinuation in 8.8% (n=6), and fatal TEAEs in 8.8%, of which 2.9% were due to COVID-19 pneumonia.

You are now leaving the website

This link is provided for information purposes only. You’ll be leaving beonemedaffairs.com and accessing a third-party website over which [BeOne Medicines | GmbH] has no control or influence.

This link will take you to a third-party website outside of beonemedaffairs.com.

[BeOne Medicines | GmbH] has no control over this website and makes no representations regarding its content or availability in your location. [BeOne Medicines | GmbH] declines any responsibility for third-party information, data usage policies, or personal data processing.

By proceeding, you acknowledge that you are part of the intended audience of the third-party website and confirm your compliance with applicable laws.

Do you want to leave beonemedaffairs.com

You are now leaving the website beonemedaffairs.com and entering another BeOne website with different terms of use. Information included on this website may not be specific to your country. Click Continue to proceed